BEAM ▲ +3.5% - Beam Therapeutics Inc. $BEAM - Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 Beam Therapeutics rose 3.5% following the presentation of updated clinical data from its Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency at the European Respiratory Society Congress. The positive clinical readout at a major medical conference typically signals progress in the company's gene therapy program and may have reinforced investor confidence in the candidate's development trajectory. 08-SEP-2026 06:00 AM ET